Center news & funding
Massey awarded American Cancer Society Institutional Research Grant for 40th year
For 40 years, the American Cancer Society (ACS) has continuously awarded VCU Massey Cancer Center $270,000 Institutional Research Grants (IRGs). The ACS-IRGs are awarded as block grants to prestigious institutions to provide funding for young investigators with an interest in cancer research.
Massey researchers and physicians receive VCU Faculty Excellence Awards
VCU Massey Cancer Center physicians and researchers were recently honored at the VCU School of Medicine’s 16th Annual Faculty Excellence Awards. Established in 1999, these awards formally recognize exceptional faculty for their leadership, mentorship and professional excellence.
Massey physicians win Best Bedside Manner Awards
VCU Massey Cancer Center physicians were recognized by the community as having the best bedside manner in the 2014 Annual Best Bedside Manner Awards presented by Our Health Richmond magazine. The public voted for medical providers in the Richmond area based on kindness, empathy and attentiveness.
The Cancer Research and Resource Center of Southern Virginia in Danville moves to new location
The Cancer Research and Resource Center of Southern Virginia in Danville has moved to a new location that is more accessible to cancer patients, survivors and their families and caregivers. After four years at the Institute for Advanced Learning and Research, the office now resides in Danville’s Main Street community at Kennedy Hall, 103 S. Main Street, formerly part of Stratford College.
Massey and VIMM researchers receive $1.8 million grant to test a promising prostate cancer immunotherapy
Virginia Commonwealth University (VCU) Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) researchers Paul B. Fisher, M.Ph., Ph.D., and Xiang-Yang (Shawn) Wang, Ph.D., have been awarded nearly $1.8 million from the Department of Defense (DOD) Prostate Cancer Research Program (PCRP) to test a promising prostate cancer immunotherapy that leverages tumor-reactive lymphocytes, a type of white blood cell, and a cancer toxic gene. The grant will allow Fisher and Wang to test this novel therapy using preclinical animal models. If successful, the team hopes to translate the research into clinical trials to further test it in patients with metastatic prostate cancer.